systems, its dysfunction is not restricted anatomically to the heart, nor is it limited in disease scope to atherosclerosis. Considering the fact that endothelial dysfunction is present in kidney allograft recipients 9 and renalase is expressed in the endothelium, the aim of the present study was to assess associations between renalase, and markers of endothelial dysfunction in kidney allograft recipients.
PAtIEnts And mEthods The study included 62 kidney allograft recipients (47 men). Before transplantation, all kidney transplant recipients were on renal replacement therapy. The immunosuppressive regimen of kidney transplant recipients consisted of calcineurin inhibitor, cyclosporine (mean levels, 162.60 ±52.71 ng/ml), in combination with mycophenolate mofetil (2 g/d) and prednisone (median, 7.5 mg/d; ranges, 0-10 mg/d). They also received antihypertensive drugs, including calcium channel blockers (100%), β-blockers (59%), angiotensin-converting inhibitors (24%), diuretics (26%), together with statins (21%).
All patients maintained sufficient and stable graft function, showed no clinical signs of rejection, or inflammation. All subjects gave written informed consent, and the protocol was approved by the Medical University Ethics Committee.
Blood was drawn in the morning when patients presented for routine control visits after an overnight fast. Glomerular filtration rate (GFR) was estimated using the 10 or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 11 Creatinine clearance was estimated using the Cockcroft-Gault formula.
12 Complete blood count, urea, phosphate, and creatinine were measured by standard laboratory methods in the central laboratory of the hospital. We evaluated thrombin activity (prothrombin fragments 1+2, Enzygnost F1+2 micro, Dade Behring, Marburg, Germany), and the degree of plasmin generation (plasmin-antiplasmin complexes [PAP] , Enzygnost PAP micro, Dade Behring) by the use of commercially available kits. Markers of endothelial injury (von Willebrand factor [vWF] , thrombomodulin) were measured using the commercially available kits from American Diagnostica, Greenwich, Connecticut, United States, and adhesion molecules (inercellular adhesion molecule, vascular cell adhesion molecule [VCAM]) were measured using the kits from R&D Systems, Quantikine, Abingdon, United Kingdom. Tissue plasminogen activator (tPA) and its inhibitor, plasminogen activator inhibitor, were assayed using the kits from Bioopol, Umea, Sweden. High-sensitivity C-reactive protein (CRP) was measured using the commercially available assay from American Diagnostica and inter leukin 6 (IL-6) using the commercially available kit from R&D Systems. Renalase was assessed using the commercially available the discovery of renalase and its possible role in hypertension. Xu et al. 6 reported that renalase had a flavin-adenine dinucleotide (FAD)-binding domain, and that FAD was an essential cofactor for the stability and its monoamine oxidase activity. Renalase is preferentially expressed in proximal tubules, but also in the glomeruli and distant tubules, cardiomyocytes, liver, and skeletal muscles 6 as well as in peripheral nerves, adrenals, endothelium, central nervous system, a 12.5-day-old rat embryo, and human adipose tissue.
6,7 It degrades catecholamines in vitro with a distinct substrate specificity and inhibitor profile, indicating that it represents a new class of flavin adenine dinucleotide-containing monoamine oxidases. It lowers blood pressure in vivo by decreasing cardiac contractility and heart rate and by preventing the expected compensatory increase in peripheral vascular tone.
8
Due to the fact that the endothelium is multifunctional and highly distributed among all organ Data are presented as mean ± standard deviation or median and ranges.
Abbreviations: CKD-EPI -Chronic Kidney Disease Epidemiology Collaboration, DBPdiastolic blood pressure, eGFR -estimated glomerular filtration rate, hsCRPhigh-sensitivity C-reactive protein, F1+2 -prothrombin fragments 1+2, ICAM -intercellular adhesion molecule, IL-6 -inter leukin 6, MDRD -Modification of Diet in Renal Disease, PAI-1 -plasminogen activator inhibitor-1, PAP -plasmin-antiplasmin complexes, SBP -systolic blood pressure, TAT -thrombin-antithrombin complexes, tPA -tissue plasminogen activator, VCAM -vascular cell adhesion molecule, vWFvon Willebrand factor kits from USCN Life Science Inc., Wuham, China. Healthy volunteers (n = 27) were included in the study to obtain normal ranges for renalase.
statistical analysis Data were expressed as means ± standard deviation (SD). The data given were analyzed using the Statistica 7.0. computer software. Normal distribution of variables was analyzed using the Shapiro-Wilk's W test. The data were also logarithmically transformed to achieve normal distribution where possible. Normally distributed data are reported as mean ± SD, nonnormally distributed data are expressed as a median and minimal-maximal value. The Spearman or Pearson correlations were calculated as appropriate with P <0.05 considered statistically significant. The multiple regression analysis was used to determine independent factors affecting dependent variables. Factors showing a linear correlation with renalase (P <0.1) were included in the analysis.
rEsuLts Clinical and bio chemical data of kidney allograft recipients are presented in tAbLE 1.
The mean serum renalase level in kidney allograft recipients was significantly higher compared with the control group (6.72 ±2.86 µg/ml vs. 3.86 ±0.73 µg/ml, P <0.001, respectively). In renal allograft recipients, renalase correlated with age (r = 0.29, P <0.05), time after transplantation (r = 0.34, P <0.01), CD44 (r = 0.49, P <0.0001), VCAM (r = 0.40, P <0.001) (FIGurE 1), serum creatinine (r = 0.49, P <0.001), eGFR (by CKD-EPI formula, r = -0.44, P <0.0001; by MDRD, r = -0.43, P <0.001; by Cockcroft-Gault, r = -0.39, P <0.01), serum phosphate (r = 0.33, P <0.05), urea (r = 0.41, P <0.01), CD146 (r=0.36, P <0.01), vWF (r = 0.26, P <0.06), thrombomodulin (r = 0.26, P <0.05) (FIGurE 2) and tended to correlate with tPA (r = 0.24, P = 0.05). In a multiple regression analysis, renalase was predicted in 58% by serum creatinine (β value, 0.33, P = 0.01), F = 4.49, SE = 2.12, and P <0.00029. In patients with eGFR over 60 ml/min, renalase was significantly lower than in patients with eGFR below 60 ml/min (5.72 ±2.02 µg/ml vs. 7.63 ±3.22 µg/ml, P <0.001). In hypertensive kidney allograft recipients, renalase was significantly higher than in normotensives (FIGurE 3). dIscussIon Even a successful kidney transplantation did not restore normal kidney function and the majority of kidney allograft recipients had stage 2 or 3 CKD. 13 It is known that CKD is related to increased cardiovascular mortality.
14 Chronic renal failure has also been associated with impaired immunity and subclinical inflammation involving cytokines derived from adipose tissue -adipocytokines. Endothelial cell injury is a common finding in patients after kidney transplantation as shown previously.
9 In humans, declining renal function may also affect the levels of inflammatory molecules, because serum CRP and IL-6 levels are inversely correlated with creatinine clearance. dependent on kidney function. Due to wide tissue distribution of renalase, its function may be organ-specific. Therefore, its synthesis and excretion might be related not only to kidney function. However, further studies are needed to prove a possible role of renalase in cardiovascular pathology, as well as in kidney allograft recipients and novel targeted therapies. Worsening renal function may enhance overall inflammatory responses because of the decreased renal clearance of factors that are directly or indirectly involved in inflammation and endothelial dysfunction.
We observed that renalase was significantly higher in kidney transplant recipients than in healthy volunteers. In patients with eGFR over 60 ml/ min, renalase was significantly lower than in patients with eGFR below 60 ml/min. In addition, renalase was related in the univariate analysis to kidney function, age, time after transplantation, and markers of endothelial dysfunction. However, in the multiple regression analysis, renalase was predicted independently by kidney function. Only one clinical study, by Schlaich et al., 16 presented also in the abstract form, showed that in patients with resistant hypertension (n = 22) arterial renalase was significantly higher in normotensive control subjects (n = 4, P <0.05). However, the whole body noradrenaline spillover tended to be higher in hypertensive patients, but without statistical significance (P = 0.12). Arterial renalase correlated negatively in univariate analysis with systolic blood pressure in the entire cohort (r = -0.52, P <0.05).
The association between renalase and hypertension was also observed by Zhao et al., 17 who were the first to show that in the Han Chinese population, the renalase encoding gene was a novel susceptibility gene for essential hypertension and its genetic variations might influence blood pressure. In Caucasian patients participating in the Heart and Soul Study, reported that a functional missence polymorphism (C allele) in renalase (Glu37Asp) was associated with left ventricular hypertrophy, systolic and diastolic dysfunction, poor exercise capacity, and inducible ischemia; however, no association between this CC genotype and blood pressure in the population of stable coronary artery disease was observed. In a recent paper, Stec et al.
19 describes polymorphisms of renalase gene and their associations with hypertension in patients on hemo dialysis. We observed previously that diastolic blood pressure together with kidney function were predictors of renalase in kidney allograft recipients, 20 but in the present study we could only notice that renalase was significantly higher in hypertensive kidney allograft recipients than in normotensives. This is the first report regarding the correlations between renalase and endothelium injury markers; however, renalase levels were predicted by kidney function. It results from the fact that as kidney function deteriorates, endothelial damage increases, which is reflected by the rise in vWF, thrombomodulin, and cytokines. It should be emphasized that renalase is secreted not only by the kidney, but also by cardiomyocytes, liver, adipose tissue, skeletal muscles, endothelium, and the central nervous system.
In conclusion, renalase, highly elevated in kidney transplant recipients, is predominantly strEszczEnIE wProwAdzEnIE Renalaza jest enzymem wydzielanym przez nerki, który powoduje degradację krążą-cych we krwi katecholamin, przez co może mieć wpływ na regulację ciśnienia tętniczego. U chorych po przeszczepieniu nerki często występuje dysfunkcja śród błonka.
cELE Celem pracy była ocena zależności pomiędzy stężeniem renalazy w surowicy, ciśnieniem tętniczym a czynnością nerek u chorych po przeszczepieniu nerki.
PAcjEncI I mEtody Morfo logia, stężenie mocznika i kreatyniny, lipidogram i glikemia na czczo zostały ocenione standardowymi metodami laboratoryjnymi. Oceniono również markery krzepnięcia: fragmenty protrombiny 1+2; markery fibrynolizy: tkankowy aktywator plazminogenu (tissue plasminogen activator -tPA), inhibitor aktywatora plazminogenu typu 1, kompleks plazmina-antyplazmina; markery funkcji/ uszkodzenia śród błonka: czynnik von Willebranda (von Willebrand factor -vWF), trombomodulinę, czą-steczki adhezyjne, cząsteczki adhezji komórkowej naczyń (vascular cell adhesion molecule -VCAM); markery stanu zapalnego: białko C-reaktywne oznaczone metodą o dużej czułości i inter leukina 6. Stężenie renalazy oceniono za pomocą powszechnie dostępnego zestawu.
wynIKI Średnie stężenie renalazy u chorych po przeszczepieniu korelowało z wiekiem, czasem po przeszczepieniu, sCD44, VCAM, stężeniem kreatyniny, oszacowanym przesączaniem kłębuszkowym (estimated glomerular filtration rate -eGFR; oszacowanym za pomocą wzorów: CKD-EPI, MDRD, Cockcrofta i Gault), stężeniem fosforanów, mocznika, sCD146, vWF, trombomoduliny oraz wykazywało tendencję do korelacji z tPA. U chorych z eGFR >60 ml/min stężenie renalazy było mniejsze niż u osób z niższym eGFR. U chorych po przeszczepieniu z nadciśnieniem tętniczym stężenie renalazy było większe niż u pacjentów bez nadciśnienia tętniczego. Analiza wielo czynnikowej regresji wykazała, że czynnikiem predykcyjnym poziomu renalazy było w 58% przypadków stężenie kreatyniny.
wnIosKI Stężenie renalazy, znacznie zwiększone u chorych po przeszczepieniu nerki, w głównym stopniu zależy od czynności nerek, która pogarsza się z wiekiem i w miarę upływu czasu po przeszczepieniu. Istnieje potrzeba przeprowadzenia dalszych badań potwierdzających przypuszczalną rolę renalazy w patogenezie nadciśnienia tętniczego u chorych po przeszczepieniu nerki oraz jej ewentualnego wykorzystania jako celu terapeutycznego.
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